Next-gen CAR-T, TCR player Autolus gains $80M for clinical trial work – Endpoints News
Endpoints News |
Next-gen CAR–T, TCR player Autolus gains $80M for clinical trial work
Endpoints News Autolus is one of a number of upstart biotechs that think better technology — like its pattern recognition tech — can make for a much better CAR-T or T cell receptor therapy personalized for each patient. These new cell therapies, they believe, will … AUTOLUS LIMITED: Autolus Secures US$80 million Series C Funding Syncona leads $80 mln round for gene therapy firm Autolus |
